Update on the therapy of Behçet disease

Ther Adv Chronic Dis. 2014 May;5(3):112-34. doi: 10.1177/2040622314523062.

Abstract

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

Keywords: Behçet disease; Behçet syndrome; biologic therapy; therapy; treatment; tumor necrosis factor α.

Publication types

  • Review